Meningococcal quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®: In Adolescents and Adults

BioDrugs

Volumn 24, Issue 5, 2010, Pages 287-297

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Meningococcal vaccine groups A C Y W 135 conjugate, general; Meningococcal vaccines, therapeutic use

Indexed keywords

ALUMINUM PHOSPHATE; ANALGESIC AGENT; ANTIPYRETIC AGENT; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; WART VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; CHILL; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DIPHTHERIA; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SEROTYPE; SINGLE DRUG DOSE; TETANUS; VACCINATION; VACCINATION REACTION;

ADOLESCENT; ADULT; BACTERIAL CAPSULES; BACTERIAL PROTEINS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNIZATION SCHEDULE; INFECTION CONTROL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 77956164294     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11204790-000000000-00000     Document Type: Review

References (18)

1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningo-coccaemia, and Neisseria meningitidis. Lancet 2007 Jun 30; 369 (9580): 2196-2210
2. Reisinger KS, Black S, Stoddard JJ. Optimizing protection against meningo-coccal disease. Clin Pediatr (Phila) 2010 Jun; 49 (6): 586-597
3. Hill DJ, Griffiths NJ, Borodina E, et al. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond) 2010 Feb 9; 118 (Pt 9): 547-564
4. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningo-coccal disease. Vaccine 2009 Jun 24; 27 Suppl. 2: B51-63
5. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Eng J Med 2001 May 3; 344 (18): 1378-1388
6. Broker M, Dull PM, Rappuoli R, et al. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009 Sep 18; 27 (41): 5574-5580
7. Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vacci-nation of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009 Dec; 16 (12): 1810-1815
8. Sanofi Pasteur Inc. Meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine Menactra®: US prescribing information [online]. Available from URL: http://www.fda.gov/downloads/ BiologicsBlood Vaccines/Vaccines/ApprovedProducts/UCM131170.pdf [Accessed 2010 Apr 26]
9. Sanofi Pasteur Inc. Menactra™ (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine): Canadian prescribing information [online]. Available from URL: http://www.menactra.ca/User Files/File/Menactra-HCP-EN.pdf [Accessed 2010 Apr 26]
10. Advisory Committee on Immunization Practices. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep 2008 May 2; 57(17)462-465
11. Novartis Vaccines. Menveo group A, C, W135 and Y conjugate vaccine: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 Apr 20]
12. Advisory Committee on Immunization Practices. Licensure of a meningo-coccal conjugate vaccine (Menveo) and guidance for use: Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 2010 Mar 12; 59(9)273.
13. Arguedas A, Soley C, LoaizaC, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glyco-conjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28 (18): 3171-3179
14. Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010 Apr; 17 (4): 537-544
15. Stamboulian D, Lopardo G, Lopez P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. Epub 2010 Jul 21
16. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an inves-tigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009 Jul 1; 49 (1): e1-10
17. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to deter-mine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009 Feb; 28 (2): 86-91
18. Gill C, Kleinschmidt A, Anemona A, et al. Antibody persistence 22 months after vaccination of adolescents with the Menveo™ conjugate vaccine or Menactra®. Poster presented at the 14th International Congress on Infectious Diseases; 2010 Mar 9-12; Miami (FL)